FOTO – Positioning for M&A Exit
Challenge:
FOTO developed software used by medical physicians to on-board new patients, document their medical diagnoses, and track treatment outcomes and recovery metrics. The three founders, all doctors themselves, had operated the company for more than a decade and wanted to exit the business. An initial acquisition offer unraveled during due diligence, and Rocket Science was engaged to re-position and re-market the company, expand the universe of potential acquirers, and maximize shareholder value ahead of a future exit.
M&A Strategy:
Upon our evaluation of the business we discovered that insurance companies would often approach FOTO to request data on patient outcomes. The company’s database of 22 million patient outcomes was rich enough that outcomes data could be segmented by patient age, gender, and even major body part (e.g. arm, leg, hip, neck, et cetera). We quickly determined that FOTO’s highest strategic value was not in its software, but in its proprietary database of patient outcomes and the predictive healthcare insights that dataset could generate. Our M&A re-positioning strategy was therefore to shift FOTO from a workflow software provider into a healthcare data intelligence company, with one of the industry’s largest outcome-based datasets.
Execution:
• Secured Board & Founder alignment around a data-centric M&A valuation strategy.
• Re-messaged investor pitch for “predictive data analytics for healthcare.”
• Rebuilt the corporate website, messaging architecture, and SEO strategy around healthcare analytics and outcomes intelligence.
• Shifted go-to-market efforts from passive inbound discovery to targeted outbound demand generation.
• Established the founders as recognized healthcare policy experts through strategic thought leadership, media articles, and collaboration with influential healthcare policy stakeholders in Washington, D.C..
Results:
• Generated 30+ articles in top-tier business press, featuring the company founders commenting on healthcare legislation and its impact on the insurance industry.
• Significantly increased sales pipeline $ value and reduced lead-to-close cycle times.
• Attracted M&A interest from strategic PE buyers looking for a data analytics piece to anchor their healthcare roll-up deals.
• Acquired by Net Health (The Carlyle Group) within 12 months of the repositioning initiative, at a substantially higher valuation than the previous failed acquisition offer.
Impact for CEOs & CMOs:
This case demonstrates a fundamental principle of Valuation Engineering: the asset that creates the greatest strategic value for an M&A buyer is often different from the product that generates current revenue. The valuation opportunity in this case was not hidden in the company’s software; it was hidden in what industry category the company operated in (software vs. data analytics). Achieving optimal valuation requires a narrative and value justification that articulates how the target can deliver outsized returns to the buyer.